Tenosynovial Giant Cell Tumor of Diffuse Type Mimicking Bony Metastasis Detected on F-18 FDG PET/CT

Chang, Kihun; Byun, Byung Hyun; Moon, Han Sol; Park, Jihyun; Koh, Jae Soo; Lim, Sang Moo

doi:10.1007/s13139-014-0275-3

Cited by 7 publications

(4 citation statements)

References 17 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Therefore, this disease can be easily mistaken for a malignant neoplasm, for example when FDG-PET is performed for staging, as in the current case. Owing to the routine use of FDG-PET as a staging study, reports of incidental findings of TGCTs mimicking malignant neoplasms are becoming more frequent …”

Section: Discussionsupporting

confidence: 78%

“…Owing to the routine use of FDG-PET as a staging study, reports of incidental findings of TGCTs mimicking malignant neoplasms are becoming more frequent. 6,7 Surgical excision of the pathologic tissue is the standard treatment of TGCT and is usually curative for the localized form. In the diffuse type, multiple and invasive surgical procedures often lead to significant adverse effects and the risk for recurrence is high.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Mass With High Uptake of Fluorodeoxyglucose on Positron Emission Tomography

2018

View full text Add to dashboard Cite

An adolescent girl presented with a 3-month history of a growing, painless mass in the right thigh. A magnetic resonance imaging (MRI) scan showed an inhomogeneous nodule in the subcutaneous layer with a largest diameter of approximately 5 cm. No enlarged lymph nodes were detectable in the groin. Results of a complete blood cell count and levels of alkaline phosphatase, lactic dehydrogenase, and C-reactive protein were unremarkable. An ultrasonography-guided core needle biopsy was performed, and histopathologic evaluation showed the aspects of a small round-cell tumor, which was confirmed to be a Ewing sarcoma by immunohistochemical and molecular analysis (with positivity for the EWS-FLI1 fusion gene [OMIM 133450]). The patient then underwent disease staging with computed tomography (CT) of the chest and whole-body fluorodeoxyglucose positron emission tomography (FDG-PET). The CT findings were negative for secondary lesions; the FDG-PET scan demonstrated, as expected, high uptake in the right thigh (maximum standard uptake variable [SUVmax], 8.4) at the site of the subcutaneous tumor and at a second lesion in the left ankle joint (SUVmax, 12.0). The patient reported vague pain around the left ankle but no functional limitations and no history of trauma at that site. A radiograph of the ankle did not show calcifications within the soft-tissue lesion. An MRI scan of the ankle showed a 1.5-cm soft tissue mass in the posterior recess of the ankle joint with a low to intermediate signal in T1-and T2-weighted sequences and moderate contrast enhancement throughout the lesion (Figure 1). Diagnosis B. Tenosynovial giant cell tumor

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

A Mass With High Uptake of Fluorodeoxyglucose on Positron Emission Tomography

2018

View full text Add to dashboard Cite

show abstract

“…2 Several case reports and small series have shown that tenosynovial giant cell tumor can show increased FDG uptake and may cause false-positive result on FDG PET/CT. [6][7][8][9][10] FDG PET/CT findings of facet joints have been rarely reported before. This case indicates tenosynovial giant cell tumor, although rare, should be included in the differential diagnosis of abnormal facet joint FDG accumulation.…”

mentioning

confidence: 99%

“…The MRI features of diffuse-type tenosynovial giant cell tumor are predominant low signal intensity on T2-weighted images and blooming of low signal intensity on gradient echo images 2. Several case reports and small series have shown that tenosynovial giant cell tumor can show increased FDG uptake and may cause false-positive result on FDG PET/CT [6][7][8][9][10]. FDG PET/CT findings of facet joints have been rarely reported before.…”

mentioning

confidence: 99%

FDG PET/CT in Tenosynovial Giant Cell Tumor of the Lumbar Facet Joint

Zhang

Zhu

et al. 2021

Clin Nucl Med

View full text Add to dashboard Cite

Tenosynovial giant cell tumor rarely affects the facet joints of the spine. We describe FDG PET/CT findings in a case of tenosynovial giant cell tumor arising from the left L2 to L3 facet joint. The tumor caused osteolytic bone destruction of the facet joint and showed intense FDG uptake with SUV max of 10.4. This case indicates tenosynovial giant cell tumor should be included in the differential diagnosis of abnormal facet joint FDG accumulation.

show abstract

Successful treatment of a diffuse type tenosynovial giant cell tumor in the thoracic spine mimicking spinal metastasis by frozen recapping laminoplasty in a patient with thyroid cancer

et al. 2018

View full text Add to dashboard Cite

TGCT-D can mimic metastasis in PET/CT and should be included in the differential diagnosis if a lytic lesion affecting the posterior elements of the vertebrae involves the facet joints. CT-guided biopsy is recommended for accurate diagnosis when an occult tumor, such as TGCT, is incidentally detected on PET-CT, even in patients with a history of malignant neoplasm. Frozen recapping laminoplasty is useful for complete resection of a spinal tumor, preventing local recurrence, and preservation of the posterior spinal elements.

show abstract

Tenosynovial Giant Cell Tumor of Diffuse Type Mimicking Bony Metastasis Detected on F-18 FDG PET/CT

Cited by 7 publications

References 17 publications

A Mass With High Uptake of Fluorodeoxyglucose on Positron Emission Tomography

A Mass With High Uptake of Fluorodeoxyglucose on Positron Emission Tomography

FDG PET/CT in Tenosynovial Giant Cell Tumor of the Lumbar Facet Joint

Successful treatment of a diffuse type tenosynovial giant cell tumor in the thoracic spine mimicking spinal metastasis by frozen recapping laminoplasty in a patient with thyroid cancer

Contact Info

Product

Resources

About